Products Affected - Description
Mercaptopurine tablets, Par
50 mg, 60 count (NDC 49884-0922-02) - discontinued
50 mg, 250 count (NDC 49884-0922-04) - discontinued
Mercaptopurine tablets, Teva
50 mg, 60 count (NDC 00093-5510-06)
Purinethol tablets, Teva
50 mg, 60 count (NDC 57844-0522-06)
Reason for the Shortage
- Par discontinued mercaptopurine tablets in October 2014.
- Teva could not provide a reason for the shortage.
Mercaptopurine tablets, Mylan
50 mg, 25 count (NDC 00378-3547-52)
50 mg, 250 count (NDC 00378-3547-25)
Mercaptopurine tablets, Roxane
50 mg, 25 count (NDC 00054-4581-11)
50 mg 250 count (NDC 00054-4581-27)
Estimated Resupply Dates
Teva has mercaptopurine and Purinethol tablets on long-term back order and the company cannot estimate a release date.
April 15, March 2, 9, and 25, February 20, 2015; November 26, August 27, May 21, March 20, January 15, 2014; November 11, September 9, July 16, June 13, May 14, April 3, March 1 and 21, 2013, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins